Halozyme Therapeutics, Inc. (HALO) was a big mover last session, as its shares rose over 9% on the day. The rise came on solid volume too with far more shares changing hands than in a normal session. This reverses the recent downtrend for the company, as the stock is now down over 10% in the past one-month time frame.
In the last 30-day frame, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Better-ranked med-biomed gene stocks include Cambrex Corp. (CBM), China Biologic Products, Inc. (CBPO) and Gilead Sciences Inc. (GILD). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
HALOZYME THERAPEUTICS INC (HALO): Free Stock Analysis Report
CAMBREX CORP (CBM): Free Stock Analysis Report
CHINA BIOLOGIC PRODUCTS INC (CBPO): Free Stock Analysis Report
GILEAD SCIENCES INC (GILD): Free Stock Analysis Report
Zacks Investment Research
Halozyme Therapeutics (HALO) Jumps: Stock Up 9.3%
Terms and Privacy Policy